Abstract:Background and aim: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat fever, pain, and inflammation. Concerns regarding their cardiovascular safety have been raised. However, the underlying mechanism behind these events remains unknown. We aim to investigate the cardiovascular safety signals and receptor mechanisms of NSAIDs, employing a comprehensive approach that integrates pharmacovigilance and pharmacodynamics. Methods: This study utilized a pharmacovigilance-pharmacodynamic approach to evaluate the cardiovascular safety of NSAIDs and explore potential receptor mechanisms involved. Data were analyzed using the OpenVigil 2.1 web application, which grants access to the FDA Adverse Event Reporting System (FAERS) database, in conjunction with the BindingDB database, which provides target information on the pharmacodynamic properties of NSAIDs. Disproportionality analysis employing the Empirical Bayes Geometric Mean (EBGM) and Reporting Odds Ratio (ROR) methods was conducted to identify signals for reporting cardiovascular-related adverse drug events (ADEs) associated with 13 NSAIDs. This analysis encompassed three System Organ Classes (SOCs) associated with the cardiovascular system: blood and lymphatic system disorders, cardiac disorders, and vascular disorders. The primary targets were identified through the receptor-NSAID interaction network. Ordinary least squares (OLS) regression models explored the relationship between pharmacovigilance signals and receptor occupancy rate. Results: A total of 201,231 reports of cardiovascular-related ADEs were identified among the 13 NSAIDs. Dizziness, anemia, and hypertension were the most frequently reported Preferred Terms (PTs). Overall, nimesulide and parecoxib exhibited the strongest signal strengths of ADEs at SOC levels related to the cardiovascular system. On the other hand, our data presented naproxen and diclofenac as drugs of comparatively low signal strength. Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) were identified as central targets. OLS regression analysis revealed that the normalized occupancy rate for either COX-1 or COX-2 was significantly inversely correlated with the log-transformed signal measures for blood and lymphatic system disorders and vascular disorders, and positively correlated with cardiac disorders and vascular disorders, respectively. This suggests that higher COX-2 receptor occupancy is associated with an increased cardiovascular risk from NSAIDs. Conclusion: Cardiovascular safety of NSAIDs may depend on pharmacodynamic properties, specifically, the percentage of the occupied cyclooxygenase isoenzymes. More studies are needed to explore these relations and improve the prescription process.

A real-world disproportionality analysis of the FDA adverse event reporting system events for ibuprofen

A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Baricitinib.

A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database

Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib

A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system

Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment

A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Ticagrelor

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases

Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis

Kidney Injury Following Ibuprofen and Acetaminophen: A Real-World Analysis of Post-Marketing Surveillance Data

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system

A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data

Insights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system

Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic Study

Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events

Adverse events associated with Atogepant: a faers-based pharmacovigilance analysis

Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis